GeneFerm Biotechnology Co., Ltd.

GeneFerm Biotechnology Co., Ltd.

1796.TWO
GeneFerm Biotechnology Co., Ltd.TW flagTaipei Exchange
36.65
TWD
+0.05
- -
1.52BMarket Cap
GeneFerm Biotechnology Co., Ltd.
1796.TWO
(Taipei Exchange)

Recent

price

36.65

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
9.27
15.6
18.23
14.02
13.02
11.78
13.2
13.16
15.33
19.15
12.57
- -
11.85
Revenue per Share
- -
-0.77
2.26
3.79
1.13
0.38
-0.99
0.16
1.45
2.26
3.01
-0.54
- -
0.54
Basic EPS, GAAP
- -
0.15
1.66
0.47
0.2
0.47
-1.6
-0.93
-0.84
-3.77
2.87
-0.35
- -
0.76
Free Cash Flow per Basic Share
- -
- -
- -
- -
2.1
1
0.5
- -
0.09
1
1.5
2
- -
- -
Dividend per Share
- -
6.38
8.64
13.09
11.7
10.94
9.26
10.16
11.73
12.53
13.79
10.95
- -
11.18
Book Value per Share
- -
7
9.26
13.38
12.57
15.12
13.93
14.16
18.81
20.07
21.49
18.97
- -
18.89
Tangible Book Value per Share
- -
24
24
25
25
27
28
28
40
41
41
41
- -
43
Basic Weighted Avg Shares
- -
223
375
453
350
357
328
368
522
634
794
521
677
511
Sales/Revenue/Turnover
- -
-8.31
14.65
25.74
10.35
2.75
-7.44
4.9
15.37
15.97
19.29
-6.81
6.8
7.64
Operating Margin (%)
- -
21
14
18
27
30
38
41
45
50
73
79
74
56
Depreciation Expense
- -
-18
54
94
28
10
-28
5
57
93
125
-23
29
23
Net Income, GAAP
- -
- -
2.47
19.33
23.39
27.18
- -
33.09
18.44
15.21
18.78
- -
16.81
16
Effective Tax Rate (%)
- -
-8.29
14.48
20.8
8.07
2.89
-8.39
1.23
10.99
14.74
15.7
-4.32
4.26
4.54
Profit Margin (%)
105
86
119
134
91
195
468
420
334
134
207
278
437
437
Working Capital
75
56
46
45
35
39
471
457
123
104
76
205
285
285
LT Debt
187
169
223
333
315
417
390
396
748
831
893
788
817
817
Total Equity
- -
- -
19.15
25.92
6.29
1.51
- -
1.34
6.14
7.51
11.71
- -
3.52
3.02
Return on Invested Capital (%)
- -
- -
21.16
27.2
6.86
2.82
- -
1.43
7.35
11.6
17.52
- -
4.52
3.6
Return on Capital (%)
- -
-11.35
30.06
35.33
9.15
3.48
-9.87
1.67
15.34
19.01
22.87
-4.39
6.16
4.96
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
38
- -
39
LT Borrowings
222
- -
205
LT Finance Leases
77
- -
79
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
41
41
41
Market Capitalization
1,877
2,479
2,083

Working Capital

FRC

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
542
- -
595
Cash, Cash Equivalents & STI
241
- -
280
Accounts Receivable, Net
95
- -
92
Inventories
170
- -
190
Total Current Liabilities
135
- -
159
Payables & Accruals
- -
- -
- -
ST Debt
38
- -
39
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.05%
19.84%
3.61%
Free Cash Flow
-97.54%
-102.36%
-619.52%
Net Income, GAAP
37.39%
183.52%
-228.12%
Sales/Revenue/Turnover
8.82%
16.8%
29.92%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
184
232
195
183
794
2024
118
116
132
155
521
2025
166
168
- -
177
677

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
0.73
1.13
0.82
- -
3.01
2024
-0.2
-0.15
-0.27
- -
-0.54
2025
0.16
0.02
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1.5
2024
- -
- -
- -
- -
2
2025
- -
- -
- -
- -
- -
Business
GeneFerm Biotechnology Co., Ltd. is a Taiwan-based biotechnology company specializing in microbial fermentation toll manufacturing and the production of bio-fermented functional ingredients and health supplements. Founded in 1999 and headquartered in Tainan, Taiwan, the company provides precision fermentation and biomass fermentation contract development and manufacturing organization (CDMO) services, supported by advanced large-scale fermentation facilities including commercial-scale fermenters and downstream processing equipment. Its core products include probiotics such as GFRena2 and TestoPro; bioactive fermented ingredients like AquaSoiivon soy extract ferment; health food items including nattokinase, red yeast rice, medicinal fungi, herbal extracts; and animal-derived products such as marine collagen peptide and d-glucosamine powder. GeneFerm's offerings cater to international pharmaceutical, biotechnology, food companies, as well as novel foods and farming supplements markets across Taiwan, the USA, Australia, Japan, Israel, Belgium, and other regions. In the last 1-2 years, GeneFerm has introduced notable innovations and received several patents. It launched the GFRena2 probiotic, which has six major patents and demonstrated efficacy through multiple international journal publications, featuring advanced coating and rapid freezing technologies to ensure probiotic viability and high survival rates in production, storage, and application. The company also developed AquaSoiivon™, a soy extract ferment with enhanced bioavailability, granted five patents in Taiwan and the U.S. Additionally, it collaborated with National Taiwan University to license TestoPro, a functional probiotic strain awarded the 20th National Innovation Award, which supports physiological regulation via enterohepatic circulation. GeneFerm has obtained various international certifications including ISO 9001, ISO 22000, HACCP, FSSC22000, KOSHER, and HALAL to ensure high manufacturing standards. It is actively expanding its precision fermentation manufacturing capacity to meet growing global demand. GeneFerm operates primarily within the biotechnology and health food sectors, focusing on precision and biomass fermentation services, microbial fermentation toll manufacturing, contract manufacturing, and ODM/OEM customized finished health products. Its target customers include pharmaceutical, biotech, and food industry clients worldwide. The company maintains a strong R&D footprint with capabilities in strain screening, medium optimization, fermentation strategy, and extraction and purification processes, positioning itself as a master of microbial fermentation dedicated to sustainable production and quality assurance in the fermented health product space.